ClinicalTrials.gg
RecruitingNCT06830044Updated Sep 24, 2026

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

A Phase 3 interventional study of Milsaperidone and Placebo in Major Depressive Disorder (MDD), sponsored by Vanda Pharmaceuticals. Recruiting at 53 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Planned enrollment
143rd of 1,323
500 · median 70
Started
2025
with 69 others
Phase 3
240 of 1,500
21 open now
Primary completion
2028-03
later than 159 of 258 live
Registered
1,381st of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 143rd largest by planned enrollment of the 1,323 interventional ones that give a count, is one of 70 that started in 2025, is one of 240 in phase 3, reaches primary completion later than 159 of the 258 other live ones, and was the 1,381st registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder

03

Conditions studied

  • Major Depressive Disorder (MDD)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient 18 to 65 years of age, inclusive;
  • Meets criteria for MDD
  • Currently having an inadequate response to antidepressant therapy as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ)

Exclusion criteria

Exclusion Criteria:

  • Within the patients lifetime, has a confirmed psychiatric diagnosis other than MDD
  • Within 6 months of Screening, has a confirmed DSM-5-TR psychiatric diagnosis other than MDD
  • Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Milsaperidone

    Drug: Milsaperidone

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Oral milsaperidone

    Also known as: VHX-896

  • DrugPlacebo

    Oral placebo

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)

    The MADRS is a clinician-rated 10 item scale. Individual item scores are summed for a total possible score of 0 to 60 with a higher score indicating increased severity of depressive symptoms.

    Time frame: 6 weeks

07

Study locations

50 of 53 sites recruiting
  • Vanda Investigational Site
    Phoenix, Arizona 85012, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Little Rock, Arkansas 72211, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Garden Grove, California 92845, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Orange, California 92868, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Redlands, California 92373, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    San Jose, California 95124, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Walnut Creek, California 94596, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Colorado Springs, Colorado 80910, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Fort Myers, Florida 33912, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Miami, Florida 33135, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Vanda Investigational Site
    Miami, Florida 33173, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Tampa, Florida 33614, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Vanda Investigational Site
    Snellville, Georgia 30078, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Chicago, Illinois 60634, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Carmel, Indiana 46032, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Boston, Massachusetts 02114, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Saint Charles, Missouri 63304, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Las Vegas, Nevada 89119, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    New York, New York 10035, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    New York, New York 10036, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Staten Island, New York 10314, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Charlotte, North Carolina 28211, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Cincinnati, Ohio 45215, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Media, Pennsylvania 19063, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Vanda Investigational Site
    Houston, Texas 77081, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Plano, Texas 75093, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Richardson, Texas 75080, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Witchita Falls, Texas 76309, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Bellevue, Washington 98007, United States
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Kardzhali, 6600, Bulgaria
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Pleven, 5800, Bulgaria
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Plovdiv, 4004, Bulgaria
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Sofia, 1202, Bulgaria
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Sofia, 1618, Bulgaria
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Sofia, 1680, Bulgaria
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Targovishte, 7700, Bulgaria
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Varna, 9020, Bulgaria
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Vratsa, 3001, Bulgaria
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Brno, 60200, Czechia
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Pilsen, 30100, Czechia
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Poruba, 70800, Czechia
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Prague, 100 00, Czechia
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Prague, 15000, Czechia
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Prague, 16000, Czechia
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Prague, 18600, Czechia
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Bialystok, 15-756, Poland
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Bialystok, 15-879, Poland
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Bydgoszcz, 85-794, Poland
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Gdansk, 80-952, Poland
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Katowice, 40-514, Poland
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Katowice, 40-600, Poland
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Suchy Las, 62-002, Poland
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
  • Vanda Investigational Site
    Torun, 87-100, Poland
    Recruiting
    • Vanda Pharmaceuticals Inc. · Contact202-734-3400
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2028, 36 months after the start.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 36 months is above that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2025
First posted
Feb 17, 2025
StartActual
Mar 3, 2025
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06830044
Responsible party
Sponsor
First posted
Feb 17, 2025
Start date
Mar 3, 2025
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Sep 24, 2026

Study contacts

Vanda Pharmaceuticals
Contact
clinicaltrials@vandapharma.com
202-734-3400

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Milsaperidone

Start the discussion